-The Hindu Obamacare and other such examples make a compelling case for seeking the right combination of roles for the public and private sector in health reform in India Nail or screw? Which is best to join pieces of wood? In carpentry, the answer is that each offers benefits depending on the application. With health care reform, the choice of public or private sector financing, delivery and regulation is subject to a...
More »SEARCH RESULT
Mala Fide Decision on Drug Prices
-Economic and Political Weekly The decision to reduce the powers of the drug pricing body goes against the interest of public health. The decision of the Government of India to withdraw the power of the National Pharmaceutical Pricing Authority (NPPA) to set price controls on drugs that are not on the National List of Essential Medicines (NLEM) raises questions on the Narendra Modi regime's commitment to people's welfare. One must ask if...
More »Drug price tug of war: people vs others -S Srinivasan
-The Hindu Business Line The media have got it wrong on price control reversal Recently, there has been a flutter in various media channels and newspapers as to how the Modi Government has reversed certain drug price control measures announced in July 2014. As a result, we are told, prices of these drugs would increase much more than pre-July levels. This was supposed to be a sequel to Modi's visit to the...
More »New hepatitis cure far too costly -Martin Khor
-Asia News Network A controversy is brewing over a new cure for hepatitis C because it is extremely expensive and patients in middle-income countries like Malaysia will find it way beyond their budget. There are an estimated 400,000 Malaysians with hepatitis C, but this is probably a significant under-estimate since many people are not aware that they have the virus. Worldwide, 170 million people live with the hepatitis C virus (HCV), and every...
More »SC agrees on urgent hearing of drug price plea
-The Telegraph The Supreme Court today agreed to take up "as early as possible" a plea challenging a recent NDA government decision that is alleged to have paved the way for a sharp rise in the prices of life-saving drugs. Petitioner Manohar Lal Sharma, a lawyer, has demanded a CBI probe into a September 22 government order that he says frees a list of medicines from pricing control. His public interest plea alleges...
More »